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Abstract
INTRODUCTION: Asthma has been recognized as a disease with two main components: airway
inflammation and airway remodeling. One particular aspect of airway remodeling, reticular basement
membrane (RBM) thickening has been noted as a feature of asthmatic airways that could contribute to
disease severity. The use of inhaled corticosteroids (ICS) has been observed to reduce inflammation in the
airways of asthmatics, but its affects on specific components of airway remodeling are still in question.
METHODS: The focus of this study was to review the current literature for the last 10 years on all studies
pertaining to RBM thickening in asthmatics and whether the use of ICS can reduce the RBM as determined
by bronchial biopsy.
RESULTS: In the four studies reviewed, RBM thickening was noted in mild, moderate, or severe asthmatics as
a group when compared to healthy controls. ICS use demonstrated a significant reduction in RBM thickness,
when compared to asthmatic subjects who only used bronchodilators for symptom control. The greatest
benefit to ICS use was noted when used at moderate to high dosages for periods longer than three months.
CONCLUSION: Long term, high dose ICS are effective at reducing RBM thickness in asthmatics. Although
RBM thickening has been correlated with other signs of asthma severity such as airway hyperresponsiveness
(AHR), further studies are needed to relate pathological changes to physiological measurements in asthma
patients.
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Abstract   
 
INTRODUCTION: Asthma has been recognized as a disease with two main components:  
airway inflammation and airway remodeling.  One particular aspect of airway remodeling, 
reticular basement membrane (RBM) thickening has been noted as a feature of asthmatic airways 
that could contribute to disease severity.  The use of inhaled corticosteroids (ICS) has been 
observed to reduce inflammation in the airways of asthmatics, but its affects on specific 
components of airway remodeling are still in question.  METHODS: The focus of this study was 
to review the current literature for the last 10 years on all studies pertaining to RBM thickening 
in asthmatics and whether the use of ICS can reduce the RBM as determined by bronchial 
biopsy.    RESULTS: In the four studies reviewed, RBM thickening was noted in mild, 
moderate, or severe asthmatics as a group when compared to healthy controls.  ICS use 
demonstrated a significant reduction in RBM thickness, when compared to asthmatic subjects 
who only used bronchodilators for symptom control.  The greatest benefit to ICS use was noted 
when used at moderate to high dosages for periods longer than three months.   CONCLUSION:  
Long term, high dose ICS are effective at reducing RBM thickness in asthmatics.  Although 
RBM thickening has been correlated with other signs of asthma severity such as airway 
hyperresponsiveness (AHR), further studies are needed to relate pathological changes to 
physiological measurements in asthma patients.  KEYWORDS:  Reticular basement membrane, 
inhaled corticosteroids, bronchial biopsy 
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Introduction 
Asthma is a chronic disease of the airways that is characterized by a group of episodic 
symptoms such as wheezing, shortness of breath, chest tightness, and cough. The exact cause of 
asthma isn't known.   However, researchers think that a combination of how inherited genes and 
environmental factors interact early in life, when the immune system is developing, causes 
asthma to develop.  One theory researchers have for what causes asthma is the "hygiene 
hypothesis." It is thought that our Western lifestyle, with its emphasis on hygiene and sanitation, 
has improved our living conditions and resulted in less frequent infections in early childhood.   
Because children no longer experience the same types of environmental exposures and infections 
as they did in the past, the development of the immune system is altered, increasing the risk for 
asthma.1 
Asthma is recognized as having two main components which can contribute to its 
severity: chronic airway inflammation and airway remodeling.2  Until recently, airway 
remodeling was thought to develop late in the disease process in response to chronic 
inflammation.3  However, recent studies show that airway remodeling is present in children with 
difficult asthma to an extent similar to that seen in adults with a longer history of asthma.4   
Chronic airway inflammation occurs as a response to injury to the tissues of the airway.  
The purpose of inflammation in a healthy individual is to repair and restore injured tissues by 
causing white blood cells, such as neutrophils, to migrate from the blood vessels into the 
surrounding, injured tissue.   Once at the site of injury, the neutrophils, acting as a part of the 
body’s natural immune response, resolve the inflammation and no lasting damage occurs.4  
However, in asthma, persistent bouts of inflammation in the airway are detrimental because the 
inflammation doesn’t ever resolve, becoming chronic in nature.  This persistent inflammation 
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leads to changes in the organization, size, and composition of cells that are present in the 
airways.5  These architectural changes, collectively, are termed airway remodeling.  
Histologically, the airways are composed of three layers of cells, the inner wall layer, the 
outer wall layer, and the smooth muscle layer.  Each layer is specialized to perform a specific 
function to promote a healthy airway.  The inner wall layer refers to simple epithelial cells, 
goblet cells, the basement membrane, and the submucosa.  The outer wall layer is composed of 
connective tissue between the smooth muscle layer and surrounding parenchyma.6  The 
remodeling that occurs within these layers of the airway include:  epithelial fragility, goblet cell 
metaplasia, thickening of the reticular basement membrane (RBM), hyperplasia of airway 
smooth muscle, and deposition of extracellular matrix.5  Airway remodeling can contribute to 
alterations in airway function such as airway hyperresponsiveness (AHR).   This abnormality in 
asthma occurs when the smooth muscle surrounding the airway overreacts, causing excessive 
airway constriction and limited airflow.  In asthma, this AHR occurs in response to levels of 
pharmaceutical or  nonpharmaceutical stimuli that would be innocuous to a healthy individual.4   
A combination of airway remodeling and AHR leads to airway obstruction resulting in the 
classic asthma symptoms of cough, wheezing, chest tightness, and shortness of breath. 
Many patients with asthma exhibit persistent AHR, and excessive airway narrowing 
despite maximal asthma therapy.   However, it is not known whether or how each component of 
airway remodeling alone or in combination, affects patients clinically.5  The purpose of this 
systematic review is to identify one component of airway remodeling and to determine what 
effect commonly prescribed pharmaceutical treatments can have on its presentation in the disease 
process of asthma.  Thickening of RBM is considered the most consistent structural change in 
the airways of asthmatics, with some studies suggesting that it is pathognomonic for asthma.7   
Although there are many components of airway remodeling that could be addressed, due 
to its focused nature, this paper seeks to address changes in the RBM.   Current guidelines 
recommend using inhaled corticosteroids to inhibit inflammation of the airway in asthmatics, 
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however, do inhaled corticosteroids mitigate the thickening of the RBM in the airways of 
patients with asthma?    
Materials and Methods 
A comprehensive literature search was compiled using the keywords: asthma, inhaled 
corticosteroids, reticular basement membrane, subepithelial reticular layer, bronchial biopsy, and 
airway remodeling on Ovid:Medline, Web of Science, EBSCO-host, and google.  Literature from 
1999 to present was reviewed and weighted towards importance at answering the clinical 
question.  These results were then compiled and analyzed.  The inclusion criteria were all 
relevant full text English language articles or data, published after 1999, that aided in explaining 
the effects of corticosteroids on the RBM in subjects with asthma and utilized bronchial biopsy 
to determine that thickness.  Exclusion criteria included articles published before 1999, animal 
studies, and studies that utilized any method besides biopsy to determine RBM thickness.    
Results 
A total of four full text English language studies were published between 1999 and 2009 
addressing the affects of corticosteroids on the RBM in asthmatic airways utilizing biopsy to 
evaluate thickness.   One of these articles, written by Ward et al, was a continuation of a previous 
study performed by some of the same researchers two years prior.  All of the studies utilized in 
this systematic review performed and evaluated other tests measuring lung function, AHR, 
airflow obstruction, and inflammation in addition to measuring RBM thickness by biopsy.  Only 
the information pertaining to RBM thickness or subepithelial reticular layer thickness and the 
affect that inhaled corticosteroids have on its thickness were considered in the conclusion.   Each 
article was reviewed and graded on the following criteria: randomization, control group, sample 
size, the dosage and duration of corticosteroids evaluated, and the method used to determine 
RBM thickness.     
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In 2002, Ward et al performed a double blinded, randomized, placebo controlled, parallel 
group study of airway inflammation, RBM thickness and bronchial hyperresponsiveness (BHR) 
in 35 asthmatics.  All subjects had been diagnosed with asthma for at least 12 months.  Subjects 
were using only inhaled salbutamol for relief of symptoms.  No subjects had received treatment 
with regular ICS or inhaled long acting beta agonists for at least 3 months beforehand.  In this 
study, inhaled Fluticasone Propionate (FP) was given via a metered dose inhaler at a dosage of 
750 micrograms daily.  Control subjects, which consisted of 22 non-asthmatic individuals with 
no underlying lung disease, were given a physically identical placebo to be used daily.  Airway 
biopsy studies, spirometric tests and methacholine challenge were performed at baseline, three 
months, six months, and twelve months of treatment.  Bronchial biopsies were performed to 
determine if thickening of the reticular basement membrane was a common characteristic in 
asthmatics and if it could be mitigated with the use of inhaled corticosteroids (ICS).   Results of 
this study showed that comparison of RBM thickness between asthmatics and normal subjects at 
baseline was variable, but there was a significantly thicker RBM in patients with asthma.  After 
three months of treatment with FP, there was no significant difference in RBM thickness in 
asthmatic subjects when compared to placebo.  However, there was a significant decrease in 
RBM thickness in these subjects noted after twelve months of FP use.8   
In 2005, Ward et al also performed a follow up study to the one performed in 2002.  In 
this study, he performed a double-blind, randomized, placebo-controlled, parallel group study of 
ICS in 35 asthmatics, with bronchoalveolar lavage (BAL) and airway endobronchial biopsy 
(EBB) for inflammatory cell profiles, spirometry, methacholine challenge, and EBB for airway 
remodeling carried out at baseline, three and 12 months.   The subjects were mild-to-moderate 
yet symptomatic, steroid naïve, atopic asthmatics.  All were using Albuterol as needed for relief 
of symptoms, with no long acting beta agonists.  Controls were 22 normal healthy volunteers.  
Like the previous study, the asthmatics were divided into two groups.  One group was given 750 
micrograms of FP twice daily while the other group was given a placebo.  Spirometry improved 
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following three months of daily FP with no further improvement with up to 12 months of daily 
FP.  AHR to methacholine improved throughout the study, with the most significant 
improvement being from three to 12 months.  BAL inflammatory cells such as esosinophils, 
neutrophils, mast cells, and leucocytes decreased following three months of daily FP with no 
further improvement with 12 months.  RBM thickness decreased in the FP group, but only after 
12 months of treatment.  EBB cell counts showed a decreased in esosinophils, mast cells, and 
leucocytes following three months of daily FP, with no further changes between three and 12 
months.9 
Shiba et al conducted a cohort study to evaluate the difference in RBM thickness and 
lung function in mild asthma.  The study included 13 healthy control subjects, 17 subjects with 
newly diagnosed mild asthma, nine subjects with mild asthma diagnosed more than 12  months 
previously, and ten subjects with mild-to-moderate asthma diagnosed more than 12  months 
previously.  The group of mild-to-moderate asthmatics had been using a daily inhalation of 
greater than or equal to 600mg of beclomethasone dipropionate (BDP) since the diagnoses of 
asthma, while the other subjects with asthma had only been using a bronchodilator.  Spirometry 
and methacholine challenge tests were performed to evaluate airflow obstruction and airway 
hyperresponsiveness.  Bronchial biopsies were obtained from each subject and the RBM was 
measured by a single pathologist in a blinded fashion.  It was concluded that the RMB thickness 
was greater in subjects with mild asthma not treated with inhaled steroids, than it was in healthy 
subjects.  Additionally, RBM thickness was significantly less in subjects who suffered from 
mild-to-moderate asthma in excess of  12 months and who were treated with 600mg daily BDP 
than in subjects with mild asthma in excess of 12 months who were only treated with a 
bronchodilator.10   
Sont et al conducted a randomized, single-blinded, prospective, parallel trial involving 75 
adults with mild-to-moderate asthma who visited a clinic every three months for two years. The 
purpose of the study was to investigate whether a treatment strategy of ICS aimed at reducing 
 12 
airway hyperresponsiveness (AHR strategy), in addition to the existing guidelines for asthma 
control (reference strategy), led to more effective control of asthma and greater improvement of 
chronic airway inflammation.  In the reference strategy, the current NIH guidelines that 
determine the dosage of ICS to be used evaluate asthma symptoms, bronchodilator use, peak 
flow variability, and forced vital capacity (FEV1).    Subjects were required to keep a diary of 
their symptoms, then a step-wise dosage of ICS was prescribed based on four different classes of 
symptom severity.  In the AHR strategy, the NIH guidelines plus another variable, AHR to 
methacholine, was evaluated.  Depending on class of symptom severity, subjects took no ICS,  
200 micrograms of Budesonide or BDP twice daily, 400 micrograms twice daily, or 800 
micrograms twice daily plus five days of low dose oral steroids.  Airway inflammation was 
measured based on the eosinophil count in the subepithelial reticular membrane and the 
thickness of the subepithelial reticular membrane as determined by fiberoptic bronchial biopsy at 
entry and after two years.   Only 55 patients agreed to undergo fiberoptic bronchoscopy.   During 
the two year follow-up, there was a significant decrease in thickness of the subepithelial reticular 
membrane within the AHR strategy group, which was much greater than the change seen in the 
reference strategy group.  Similar results were obtained when restricting the analysis to subjects 
who were already using inhaled steroids at entry into the study.11  
Discussion 
The limitation of performing any study on the RBM, is that the best way to assess its 
characteristics, is through direct visualization.  This can only be achieved through performing a 
bronchial biopsy.  Unfortunately, due to the invasive nature of this procedure, it is often difficult 
to recruit subjects who are willing to undergo this kind of testing.  Therefore, the number of 
studies that have been performed utilizing bronchial biopsy to evaluate RBM thickness, before 
and after the use of inhaled corticosteroids, is limited.   
In the four studies reviewed, there were differences in methodology, sample size, severity 
of asthma, length of study, corticosteroid utilized and dosage of corticosteroid utilized.  Also, 
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there was considerable variability noted in the RBM thickness between asthmatic and normal 
subjects.  This finding might suggest that the presence of RBM thickness doesn’t discriminate 
individual asthmatic patients from healthy subjects in the unequivocal manner implied by some 
researchers.  However, in all of the studies reviewed, a significantly thickened RBM was present 
in asthmatic patients as a group and was shown to be reduced with at least three month use of 
moderate to high dose ICS.  However, a reduction in the thickness of the RBM by use of ICS is 
only helpful information if it can provide a correlation in a clinical setting. 
  In the 2002 study performed by Ward et al, it was determined that after three months of 
treatment with 750 micrograms of FP, the asthmatic subjects had very little change in AHR as 
determined by methacholine challenge, even though lung function was improved as determined 
by FEV1.  Between three and 12 months, there was a much greater improvement in AHR, while 
asthma symptoms continued to be stable and controlled.  This greater secondary improvement in 
AHR was associated with a concurrent reduction in RBM thickness, 90% of which also occurred 
from the time frame of three to 12 months.  This finding suggests that there is a significant link 
between AHR and RBM thickening in asthma, even if the symptoms of asthma appear to be in 
good control.   
In the 2005 Ward et al follow up study, inflammatory parameters measured in solid 
tissue, airway biopsies, were used to better demonstrate airway inflammation, RBM thickening, 
and AHR.  The strength of this study is that it was performed in the same manner that the 
previous one was and proceeded to show the same results as the first study in regards to a 
decrease of RBM thickening from three to 12 months use of 750 micrograms of FP daily.  
Additionally, endobronchial biopsies (EBB) were performed to determine if there was a 
significant correlation between eosinophil cell count and AHR.  After three months of treatment 
with FP, the eosinophil cell counts had decreased in the asthmatic subjects, but there were no 
further changes from three to 12 months.  However, AHR did improve from three to 12 months 
of daily FP, as previously demonstrated.  This finding indicates that the improvement in AHR 
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was not related to decreased airway inflammation, but instead could be related to a decrease in 
RBM.   
In the 2002 Shiba et al study, ten of the 49 subjects had mild-to-moderate asthma and 
used ICS to prevent exacerbations.  The remaining 39 subjects had mild asthma and used only 
bronchodilators to treat symptoms.  The results of this study showed that RBM thickening was 
present even in subjects with mild asthma.   Additionally, there was significant RBM thickening  
in mild asthmatics that had been diagnosed within 1 year, as compared to non-asthmatic controls.  
These findings confirm the idea that airway remodeling takes place early in the disease process 
and even with a mild form of the disease.  Also it was shown that RBM thickening in mild 
asthmatics not treated with ICS was negatively correlated with FEV1 and AHR.  This suggests 
that even in mild disease, the presence of RBM thickening could be responsible for decreased 
lung function and airflow.   
In the Sont et al study, the dosage of ICS utilized by one group of subjects was 
determined by asthma symptoms, bronchodilator use, peak flow variability, and FEV1.   The 
other group of subjects was evaluated with the additional variable of AHR to methacholine.  
These subjects were consistently found to have AHR and thus were prescribed higher dosages of 
ICS.  This indicates that the added variable of increased AHR can be present when all the other 
tests for evaluation of asthma severity indicate that the condition is stable and controlled.  
Furthermore, this study showed that the subjects whose ICS dosage was determined by 
evaluating AHR had a 1.8 fold lower exacerbation rate than the group of subjects whose ICS 
dosage was determined by evaluating conventional asthma severity markers.  This finding 
suggests that perhaps AHR is a better marker of asthma severity than FEV1, peak flow, and 
subjective asthma symptoms.  If this is the case, and AHR has been shown to be linked to RBM 
thickening, perhaps the current clinical management of asthma should center around treating 
AHR which has been shown to improve with use of daily ICS to target RBM thickening.   
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Conclusion 
Airway remodeling is a complex phenomenon that includes a variety of structural 
changes whose specific contribution to the clinical presentation of asthma needs further analysis.  
One specific component of airway remodeling, RBM thickening, is an early, persistent finding in 
histological studies of asthmatic airways of all ages. Even though its studies are limited in 
number, it appears that this thickening can be mitigated with a course of moderate to high dose 
ICS for greater than three months.  Additionally, it appears that the current objective indicators 
of asthma severity such as FEV1 and peak flow are not nearly as important as AHR in the long 
term control of exacerbations.  Finally, because there is some evidence that AHR and RBM 
thickening are correlated, ICS should be initiated with the diagnosis of asthma, even in patients 
with a mild form of the disease. 
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